Safety and immunogenicity of a bivalent cytomegalovirus DNA vaccine in healthy adult subjects.

Publication Type:

Journal Article


The Journal of infectious diseases, Volume 197, Issue 12, p.1634-42 (2008)


2008, Adolescent, Adult, Antibodies, Viral, CYTOMEGALOVIRUS, Cytomegalovirus Vaccines, Dose-Response Relationship, Immunologic, Female, Humans, Immunologic Memory, Kinetics, Male, T-Lymphocytes, Time Factors, Vaccine and Infectious Disease Institute, Vaccines, DNA


VCL-CB01, a candidate cytomegalovirus (CMV) DNA vaccine that contains plasmids encoding CMV phosphoprotein 65 (pp65) and glycoprotein B (gB) to induce cellular and humoral immune responses and that is formulated with poloxamer CRL1005 and benzalkonium chloride to enhance immune responses, was evaluated in a phase 1 clinical trial.